Mari Anne Snow, CEO, EASCRA Biotech, talks space pharma, making money with space medicine, targeted medical products and more. I promise, a program on this subject like none other !

Listeners: Watch the video if you can as our guest uses excellent visuals that are more than helpful.

Meeting assets for Space Show with Mari Anne Snow of Eascra, a Nanomedicine company are ready!

The following assets for the meeting - Space Show with Mari Anne Snow of Eascra, a Nanomedicine company are now available.

Our program began with guest Mari Anne Snow, CEO of EASCRA Biotech, focusing ion on the Eascra Biotech's innovative work in nanomedicine, including their space missions and development of Janus-based nanoparticles for medical applications. The discussion concluded with detailed exploration of the company's space-based manufacturing processes, potential profitability, and future plans for clinical trials and product development. Joining us in the Zoom meeting were Dr. A.J. Kothari, John Jossy, and Dr. Phil Swan. All of us spoke feely during the program.

David and Mari discussed the potential of regenerative medicine and its impact on orthopedic surgeries, particularly knee and hip replacements. Mari emphasized that their target customers are not orthopedic surgeons but rather payers and patients, as insurance often covers traditional replacements more readily than alternative treatments. They explored the market opportunities in conditions like osteoarthritis and neuromuscular injuries, as well as kidney diseases, with the goal of offering cost-effective and innovative treatments. David expressed interest in these topics and mentioned his experience with space medicine, noting the lack of awareness among doctors about emerging space medical technologies.

Mari, the Co-founder and CEO of Esker Biotech, discussed her company's innovative work in nanomedicine, focusing on precision therapy delivery solutions for various medical applications. She highlighted their progress, including completing five space missions in 24 months, as evidence of advancements in the commercial space economy. Mari explained that while Eascra is still in early stages and preclinical, they are gathering data to approach the FDA for regulatory approval of space-made products, with the goal of ensuring their space-produced items are equivalent to those made on Earth. The discussion also touched on the company's background, Mari’s experience, and the technical aspects of their work, including the challenges and opportunities in the space and medical fields.

Mari discussed her company’s journey from an academic spin-off of the University of Connecticut to becoming a space medicine company. She explained how the company initially focused on producing nanoparticles on Earth but transitioned to space-based manufacturing after receiving funding and opportunities from NASA's In Space Manufacturing Program. Mari detailed their successful space missions, including working with astronauts like Sunita Williams and Johnny Kim, and described their plans to automate future experiments for increased efficiency.

Mari explained her company's development of Janus-based nanoparticles for medical applications, including mRNA delivery for osteoarthritis treatment and a cell-free scaffold for cartilage regeneration. She described the nanoparticles' unique structure and delivery mechanism, which allows for better cell penetration and bioactivity compared to existing options. Mari also highlighted the advantages of producing these products in space, where microgravity leads to a more uniform and structurally sound scaffold, resulting in improved tissue regeneration and faster healing rates. Note that I did briefly stop her to explain “Janus-based nanoparticles,” a definition and explanation that was definitely helpful.

Mari explained their work on developing medical products, both on Earth and in space, and discussed their progress in gaining FDA approval for their space-created medical product. She mentioned that they have early-stage agreement with the FDA for establishing equivalency between Earth and space samples. David asked about the mechanism for FDA approval of space-created medical products, to which Mari responded that they need to develop this pathway. Mari also addressed David's questions about funding and potential budget cuts, stating that they have stable funding from NASA and an Innovation Grant for a cancer application. She mentioned that they are building relationships with the Department of Defense and SpaceWorks to explore additional funding opportunities and potential applications of their product for troops and long-distance space travel.

Our discussion continued focusing on the company's work with Janus-based nanoparticles and their development in microgravity, which has resulted in structural improvements of over 40% due to the lack of sedimentation and convection. Mari explained that her partner, a biomedical engineer at the University of Connecticut, has developed these technologies with funding from various sources including NIH, NSF, and NASA. The company is exploring partnerships with private space companies and has relationships with Axiom, Vast, and others to determine if parabolic flights or autonomous platforms could be sufficient for their needs. They are also considering lunar applications, though questions remain about the effectiveness of 1.6G on the moon compared to microgravity. Note that our Zoom participants were asking our guest many technical and engineering questions during this discussion though their questions were not specifically mentioned in this AI summary.

Our Space Show team discussed the potential profitability of producing medical materials in space, with Mari explaining that financial models show the venture could be profitable even at small volumes due to premium pricing similar to existing drugs like CAR T cells (for those of you not familiar with this therapy, check it out here: Home - Explore CAR T). Phil offered to share data on launch costs to various orbits, while the group explored questions about future production environments and subsidies. John inquired about clinical indications for human trials, to which Mari explained they would act as a delivery component for licensing partners, with initial in-house products likely focusing on musculoskeletal conditions like osteoarthritis, where there are currently no effective treatments. AJ also offered to share some of his data with Mari.

We discussed manufacturing processes and requirements for space-based medicine production. Mari explained they are currently in proof of concept phase with small batch production, aiming to develop an autonomous production process before scaling up. They confirmed having conversations with Varda and the Explorer company. The production process requires 48 hours in microgravity, making suborbital flights impractical, and the product maintains bioactivity for 6 months at ambient temperature, with plans to test longer-term stability.

As we were moving toward the end of our program, Mari focused on three main questions about her company's space products (listen for them in the program). Mari explained that while they have a 10-year timeline to profitability if costs continue to decrease the timeline might shorten. She said they are already generating revenue from Earth-made products. She highlighted their advantage in delivering various types of nucleic acids and drugs due to their tubular structure, noting plans to test cancer applications with RNA and an FDA-approved drug in early 2026. The conversation also revealed that there are millions in potential healthcare solutions blocked by current delivery mechanisms, with Mari's company potentially addressing this issue through their technology, which has already attracted interest from gene editing companies.

Mari discusse